RE: ⬆️⬆️ 22% and climbing ⬆️⬆️18 Jul 2025 09:34
And for those that aren’t aware - here is what we have with IMM in summary:
-Developing clinical programs for P140 in Phase 3 for Systemic Lupus Erythematosus (SLE) (Lupuzor™) and P140 in a pivotal Phase 2/3 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-Advancing preclinical programs using our proprietary technology to program the ADMET properties of peptides, as well as small molecules with bioavailability limitations
-Unlocking value through strategic licensing, partnerships, and collaborations
-Creating near-term shareholder value with our late stage, lead asset, P140 and providing significant opportunities throughout our pipeline